Inbody Co., Ltd. (041830) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Inbody Co., Ltd. (041830:KRX), powered by AI.

Current Price
₩45,550
P/E Ratio
20.0
Market Cap
614.1B
Sector
Common Stock
What is the Inbody Co., Ltd. stock price forecast?

Inbody Co., Ltd. is currently trading at ₩45,550. View real-time AI analysis on Alpha Lenz.

What is Inbody Co., Ltd. insider trading activity?

View the latest insider trading data for Inbody Co., Ltd. on Alpha Lenz.

What is Inbody Co., Ltd.'s P/E ratio?

Inbody Co., Ltd.'s P/E ratio is 20.0.

Inbody Co., Ltd.

KRX · 041830
₩45,550+1,200(+2.71%)Market closedKRX regular session 09:00–15:30 KST
Ask about Inbody Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Inbody Co., Ltd. trades at a P/E of 20.0 (fair value) with solid ROE of 10.4%. 3Y revenue CAGR of 13.5% highlights clear growth momentum.

Ask for details

Company Overview

Inbody Co., Ltd. is a company that specializes in developing and manufacturing medical and healthcare equipment focused on body composition analysis. The primary function of Inbody is to provide precise and easy-to-use products that assess body composition and health metrics, facilitating accurate assessments of various body components like fat, muscle, and water levels. These analyses are utilized in diverse sectors, including healthcare, fitness, sports medicine, and wellness, empowering professionals and patients alike with actionable insights to improve health outcomes. Inbody's innovative technology plays a crucial role in preventive health strategies, offering critical data for individual health assessments and population health management. Its products are distributed globally and are integral in medical settings, fitness centers, and research institutions. With a commitment to accuracy and reliability, Inbody Co., Ltd. has established itself as a leader in the body composition analysis industry, contributing significantly to advancements in personal health management and clinical diagnostics. In this way, the company holds a vital market position, promoting greater awareness and understanding of body health through technologically advanced solutions.

CEO차기철 (단독대표)
SectorCommon Stock
IndustryCommon Stock
0

Company Statistics

FY 2025

Profile

₩614,054,175,100Market Cap
₩233,948,308,370Revenue
13.48MShares Out
0Employees

Margins

77.37%Gross
20.85%EBITDA
15.71%Operating
16.50%Pre-Tax
12.82%Net

Valuation

20.05P/E
1.93P/B
2.62EV/Sales
11.77EV/EBITDA
21.66P/FCF

Growth (CAGR)

13.50%Rev 3Yr
16.91%Rev 5Yr
-3.35%Op Inc 3Yr
13.99%Op Inc 5Yr
-3.94%Net Inc 3Yr
11.30%Net Inc 5Yr

Returns

8.99%ROA
10.37%ROE
11.73%ROIC

Financial Health

₩52,371,957,700Cash & Cash Equivalents
₩-11,099,154,440Net Debt
12.91%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Inbody Co., Ltd. (ticker: 041830) is a company listed on KRX in the Common Stock sector (Common Stock). Market cap is $614.1B.

The current price is ₩45,550 with a P/E ratio of 20.05x and P/B of 1.93x.

ROE is 10.37% and operating margin is 15.71%. Annual revenue is $233.9B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Inbody Co., Ltd. (041830) Stock Forecast 2026 ₩45,550 — Price, Financials & Analyst Targets | Alpha Lenz